Clovis Oncology, Inc.
42
1
5
19
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
35.7%
15 terminated/withdrawn out of 42 trials
55.9%
-30.7% vs industry average
5%
2 trials in Phase 3/4
121%
23 of 19 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (42)
Pan Tumor Rollover Study
Role: collaborator
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
Role: collaborator
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Role: collaborator
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
Role: collaborator
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Role: collaborator
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
Role: collaborator
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
Role: collaborator
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Role: collaborator
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Role: collaborator
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Role: collaborator
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
Role: collaborator
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Role: collaborator
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
Role: collaborator
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Role: collaborator
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
Role: collaborator
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
Role: collaborator
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
Role: collaborator
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Role: collaborator
Rucaparib in Nonmetastatic prOstAte With BRCAness
Role: collaborator
Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
Role: collaborator